, Volume 9, Issue 1–3, pp 41–47 | Cite as

Preliminary observations using HIV-specific transfer factor in AIDS

  • Giancarlo Pizza
  • Francesco Chiodo
  • Vincenzo Colangeli
  • Francesco Gritti
  • Enzo Raise
  • Hugh H. Fudenberg
  • Caterina De Vinci
  • Dimitri Viza


Twenty five HIV-1-infected patients, at various stages (CDC II, III and IV) were treated orally with HIV-1-specific transfer factor (TF) for periods varying from 60 to 1870 days. All patients were receiving antiviral treatments in association with TF. The number of lymphocytes, CD4 and CD8 subsets were followed and showed no statistically significant variations. In 11/25 patients the number of lymphocytes increased, whilst in 11/25 decreased; similarly an increase of the CD4 lymphocytes was observed in 11/25 patients and of the CD8 lymphocytes in 15/25. Clinical improvement or a stabilized clinical condition was noticed in 20/25 patients, whilst a deterioration was seen in 5/25. In 12/14 anergic patients, daily TF administration restored delayed type hypersensitivity to recall antigens within 60 days. These preliminary observations suggest that oral HIV-specific TF administration, in association with antiviral drugs, is well tolerated and seems beneficial to AIDS patients, thus warranting further investigation.

Key words

AIDS cell-mediated immunity CD8 cytotoxic T lymphocytes HIV transfer factor 



cell equivalent


cell-mediated immunity




delayed type hypersensitivity


Kaposi’s sarcoma


leucocyte migration test




transfer factor


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Steele RW, Myers MG & Vincent MM. Transfer factor for the prevention of varicella zoster infection in childhood leukemia. New Engl J Med 1980; 303: 355–359.PubMedCrossRefGoogle Scholar
  2. 2.
    Viza D, Rosenfeld F, Phillips J, Vich JM, Denis J, Bonissent JF, Dogbe K. Specific bovine transfer factor for the treatment of herpes infections. In: Kirkpatrick CH, Burger DR, Lawrence HS, eds. Immunobiology of transfer factor. New York: Academic Press, 1983; 245–259.Google Scholar
  3. 3.
    Dwyer JM: The use of antigen specific transfer factor in the management of infections with herpes viruses. In: Immunobiology of Transfer Factor. Eds. Kirkpatrick CH, Burger DR & Lawrence HS. New York: Academic Press, 1983: 233–42.Google Scholar
  4. 4.
    Viza D, Vich JM, Phillips J, Rosenfeld F. Orally administered specific transfer factor for the treatment of herpes infections. Lymphok Res 1985; 4: 27–30.Google Scholar
  5. 5.
    Viza D, Vich JM, Phillips J, Rosenfeld F, Davies DAL. Specific transfer factor protects mice against lethal challenge with herpes simplex virus. Cell Immun 1986; 100: 555–62.CrossRefGoogle Scholar
  6. 6.
    Roda E, Viza D, Pizza G, Mastroroberto L, Phillips J, De Vinci C & Barbara L. Transfer factor for the treatment of HBsAgpositive chronic active hepatitis. P Soc Exp Med 1985; 178: 468–475.Google Scholar
  7. 7.
    Neequaye J, Viza D, Pizza G, Levine PH, De Vinci C, Ablashi DV, Biggar RJ & Nkrumah FK. Specific transfer factor with activity against Epstein-Barr virus reduces late relapse in endemic Burkitt’s lymphoma. Anticanc R 1990; 10: 1183–1187.Google Scholar
  8. 8.
    Nkrumah F, Pizza G, Viza D, Phillips J, De Vinci C & Levine P. Regression of progressive lymphadenopathy in a young child with acute cytomegalovirus (CMV) infection following the administration of transfer factor with specific anti-CMV activity. Lymphok Res 1985; 4: 237–241.Google Scholar
  9. 9.
    Viza D., Lefesvre A., Patrasco M., Phillips J., Hebbrecht N., Laumond G., Vich J.M. A preliminary report on three AIDS patients treated with anti-HIV specific transfer factor. J Exp Path 1987; 3: 653–659.Google Scholar
  10. 10.
    Carey J, Lederman M, Toosi Z, Edmonds K, Hodder S, Calatrese L, Proffitt M, Johnson C, Ellner J. Augmentation of skin test reactivity and lymphocyte blastogenesis in patients with AIDS treated with Transfer Factor, JAMA 1987;257:651–55.PubMedCrossRefGoogle Scholar
  11. 11.
    Popovic M, Sarngadharan MG, Read E & Gallo RC. Detection isolation and continuous production of cytopathic human T-lymphotrophic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984; 224: 497–500.PubMedCrossRefGoogle Scholar
  12. 12.
    Viza D, Boucheix CI, Césarini JP, Ablashi DV, Armstrong G, Levine PH, Pizza G. Characterization of a human lymphoblastoid cell line, LDV/7, used to replicate transfer factor and immune RNA. Biol Cell 1982; 46: 1–10.Google Scholar
  13. 13.
    Viza D, Goust JM, Moulias R, Trejdosiewicz LK, Collard A, Mueller-Bérat N. In vitro production of transfer factor by lymphoblastoid cell lines. Transplan P 1975; VII (suppl. 1): 329–33.Google Scholar
  14. 14.
    Søberg M, Bendixen G. Human lymphocyte migration as a parameter of hypersensitivity. Acta Med Scand 1967; 181: 247–53.Google Scholar
  15. 15.
    Centifanto YP, Zam ZS, McNeil JL, Kaufman HE. Leukocytes migration inhibitory factor in HSV infections. Invest Ophtalm Vis Sci 1978; 17: 863–68.Google Scholar
  16. 16.
    Ross CE, Cochran AJ, Hoyle DE, Grant RM, Mackie RM. Formalin-fixed tumour cells in the leukocytes migration test. Lancet, 1973; ii, 1087.CrossRefGoogle Scholar
  17. 17.
    Gottlieb MS, Zackin RA, Fiala M, Henry DH, Marcel AJ, Combs KL, Vieira J, Liebman HA, Cone LA, Hillman KS & Gottlieb AA. Response to treatment with the leukocytederived immunomodulator IMREG-1 in immunocompromised patients with AIDS-related complex: A multicanter, doubleblind, placebo-controlled trial. Ann Int Med 1991; 115: 84–91.PubMedGoogle Scholar
  18. 18.
    Gottlieb AA, Sizemore RC, Gottlieb MS & Kern CH. Rationale and clinical results of using leucocyte-derived immunosupportive therapies in HIV disease. Biotherapy, this issue.Google Scholar
  19. 19.
    Dolan MJ, Clerici M, Blatt SP, Hendrix CW, Melcher GP, Boswell RN, Freeman TM, Ward W, Hensley R & Shearer GM. In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. J Infect Dis 1995; 172: 79–87.PubMedGoogle Scholar
  20. 20.
    Fernandez-Ortega C, Dubed M, Ruibal O, Vilarrubia OL, Menéndez de San Pedro JC, Navea L, Ojeda M & Araña MJ. Inhibition of in vitro HIV infection by dialysable leucocyte extracts. Biotherapy, this issue.Google Scholar
  21. 21.
    Pizza G, Viza D, De Vinci C, Palareti A, Cuzzocrea D, Fomarola V & Baricordi V. Orally administered HSV-specific transfer factor (TF) parevents genital or labial herpes relapses. Biotherapy, this issue.Google Scholar
  22. 22.
    Viza D. “The AIDS panic” Nature 1985; 317: 281.PubMedCrossRefGoogle Scholar
  23. 23.
    Auger I, Thomas P & DeGruttola V. Incubation periods for pediatric AIDS patients. Nature 1988; 336: 575–77.PubMedCrossRefGoogle Scholar
  24. 24.
    Clerici M, Berzofsky JA, Shearer GM & Tacket CO. Exposure to human immunodeficiency virus type I; specific T helper cell responses before detection of infection by polymerase chain reaction and serum antibodies. J Infect Dis 1991; 164: 178–82.PubMedGoogle Scholar
  25. 25.
    Clerici M, Giorgi JV, Chou CC, Gudeman VK, Zack JA, Gupta P, Ho HN, Nishanian PG, Berzofsky JA & Shearer GM. Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent exposure to HIV-1. J Infect Dis 1992; 156: 1012–19.Google Scholar
  26. 26.
    Viza D. AIDS and Transfer Factor: Myths, Certainties and Realities. Biotherapy, this issue.Google Scholar
  27. 27.
    Barrow P, Lewicki H, Hahn BH, Shaw GM & Oldstone MBA. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68: 6103–10.Google Scholar
  28. 28.
    Rowland-Jones A, Sutton J, Ariyoshi K, Dont T, Gotch F, McAdam S, Whitby D, Sabally S, Gallimore A, Corrah T, Takaguchi M, Schultz T, McMichael A & Whittle H. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nature Medicine 1995; I: 59–64.CrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Giancarlo Pizza
    • 1
  • Francesco Chiodo
    • 2
  • Vincenzo Colangeli
    • 2
  • Francesco Gritti
    • 3
  • Enzo Raise
    • 3
  • Hugh H. Fudenberg
    • 4
  • Caterina De Vinci
    • 1
  • Dimitri Viza
    • 5
  1. 1.Immunodiagnosis and Immunotherapy Unit, Ist-Division of UrologyS. Orsola-Malpighi HospitalBolognaItaly
  2. 2.Institute of Infectious DiseasesOspedale S. Orsola-MalpighiBolognaItaly
  3. 3.Dept. of Infectious Diseases and Immunopathology UnitOspedale MaggioreBolognaItaly
  4. 4.Neuro Immuno Therapeutics Found.SpartanburgUSA
  5. 5.Laboratoire d’Immunobiologie, URA 1294 CNRSFaculté de Médecine des Saints-PèresParisFrance

Personalised recommendations